ABL1 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

AKT1 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

BCR is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BCR status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

CBL is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CBL status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

CRKL is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

CSF3R is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CSF3R status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains DEK status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

EZH2 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FBXW7 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 2 clinical trials for myeloid neoplasm, of which 2 are open and 0 are closed. Of the trials that contain FGFR1 status and myeloid neoplasm as inclusion criteria, 2 are phase 2 (2 open) [3].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR4 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 2 clinical trials for myeloid neoplasm, of which 2 are open and 0 are closed. Of the trials that contain FLT3 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

GATA1 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains GATA1 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

GATA2 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains GATA2 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

JAK2 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 2 clinical trials for myeloid neoplasm, of which 2 are open and 0 are closed. Of the trials that contain KMT2A status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

KRAS is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

MECOM is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

MPL is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MPL status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

MTOR is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

MYD88 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MYD88 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NOTCH1 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

NUP214 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NUP214 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 2 clinical trials for myeloid neoplasm, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

PHF6 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN is an inclusion eligibility criterion in 2 clinical trials for myeloid neoplasm, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RB1 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RB1 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RPN1 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

RUNX1 is an inclusion eligibility criterion in 2 clinical trials for myeloid neoplasm, of which 2 are open and 0 are closed. Of the trials that contain RUNX1 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

SF3B1 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

SRSF2 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SRSF2 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

STAT3 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains STAT3 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is an inclusion eligibility criterion in 2 clinical trials for myeloid neoplasm, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

U2AF1 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains U2AF1 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

WT1 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

ZRSR2 is an inclusion eligibility criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ZRSR2 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].